Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics, Inc. (AQST) reported that it has resubmitted its New Drug Application to the FDA for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The resubmission follows a January 30, 2026 Complete Response Letter requesting a human factors study on packaging/administration and a confirmatory pharmacokinetic study.
The company completed both studies using revised packaging and instructions for use, reporting that median pouch-opening time fell from 17 seconds to 3 seconds and opening-plus-administration time from 46 seconds to 17 seconds, with no protocol-defined use errors in the self-administration arm. Pharmacodynamic responses in self-administration were generally in line with clinician-administered results. Aquestive also highlights that 32–40 million people in the U.S. are at chronic risk for severe Type I reactions and cites an epinephrine market that could reach about $2.03 billion by 2029.
Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber sold 25,000 shares of common stock on September 15, 2026 in an open-market transaction under a Rule 10b5-1 trading plan. The weighted average sale price was $4.8195 per share, with prices ranging from $4.78 to $4.90.
Following this transaction, Barber directly holds 652,317 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics, Inc. (AQST) is the issuer for which Daniel Barber has filed a Form 144 notice to sell up to 50,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC on or after September 15, 2026. The shares relate to restricted stock units that vested during the period from March 7, 2026 through March 9, 2026. The notice reports an aggregate market value for the planned sale of $244,000 and notes that 125,511,648 shares of common stock are outstanding, with the stock listed on NASDAQ.
The filing also lists prior sales during the past three months under a Rule 10b5-1 trading plan, including 25,000 shares of common stock sold on August 17, 2026 for $107,167.50, 20,369 shares sold on July 16, 2026 for $81,508.59, and 4,631 shares sold on July 15, 2026 for $18,683.50.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Commercial Officer Sherry Korczynski exercised stock options and sold shares on September 9, 2026. She exercised 8,750 non-qualified stock options at an exercise price of $2.65 per share, converting them into 8,750 shares of common stock, and then sold 8,750 common shares at $5.22 per share. Following the option exercise, she held 26,250 stock options directly, with the exercised option series expiring on March 7, 2035. The sales were made pursuant to a previously adopted Rule 10b5-1 Trading Plan, indicating they were pre-arranged.
Aquestive Therapeutics, Inc. (AQST) reported that Chief People Officer Peter E. Boyd exercised a Common Stock Purchase Warrant on September 9, 2026 to acquire 2,293 shares of common stock at an exercise price of $0.96 per share, a cash exercise of a warrant issued in June 2022. The corresponding warrant position of 2,293 warrant rights was fully exercised, leaving no remaining warrants from this grant, and Boyd now holds 284,024 shares of Aquestive common stock directly. No Rule 10b5-1 trading plan is reported for these transactions.
Aquestive Therapeutics, Inc. (AQST) reported that President and CEO Daniel Barber exercised a Common Stock Purchase Warrant for 91,743 shares of common stock on September 8, 2026 at an exercise price of $0.96 per share for cash, increasing his direct common stock holdings to 677,317 shares and exhausting the warrant.
Aquestive Therapeutics, Inc. (AQST) is the issuer for a planned resale of its common stock reported under Rule 144 by officer Sherry M. Korczynski. The notice covers up to 8,750 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, arising from an exercise of stock options for cash, with an approximate aggregate market value of $45,587.50, and a stated sale date of September 9, 2026 on NASDAQ.
Aquestive Therapeutics, Inc. (AQST) reported that Chief Operating Officer Cassie Jung exercised a warrant to acquire 4,587 shares of Common Stock on September 3, 2026 by paying an exercise price of $0.96 per share, in a transaction not reported as made under a Rule 10b5-1 plan.
The related warrant, originally issued on June 8, 2022 under a Securities Purchase Agreement dated June 6, 2022, became exercisable on December 8, 2022 and expires on June 8, 2027, and now reflects 0 warrants remaining after the exercise. Following this transaction, Jung holds 206,833 shares of Common Stock directly and 2,000 shares indirectly through her spouse.
Aquestive Therapeutics, Inc. (AQST) reported that its President and CEO, Daniel Barber, sold common stock pursuant to a Rule 10b5-1 trading plan. On 2026-08-17, he sold 25,000 shares of common stock in open market or private transactions at a weighted average price of $4.2867 per share, with individual sale prices ranging from $4.24 to $4.35 per share. Following this transaction, Barber directly holds 585,574 shares of Aquestive Therapeutics common stock.
Aquestive Therapeutics, Inc. executive Sherry Korczynski, Chief Commercial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-14, 2,714 shares of common stock were withheld by the issuer at $4.25 per share to satisfy her tax withholding obligation arising from the vesting of previously granted Restricted Stock Units (RSUs). After this tax-withholding disposition, she directly holds 235,689 shares of Aquestive Therapeutics common stock.